Key takeaways
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are both combination therapies used to treat HIV, but they have some key differences. Atripla includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), while Genvoya contains two NRTIs, an integrase strand transfer inhibitor (INSTI), and a "booster" medication. Atripla must be taken on an empty stomach, preferably at bedtime, whereas Genvoya should be taken with food. Atripla is available as a generic, making it more affordable, but it is no longer a first-choice treatment due to its side effects, such as dizziness and abnormal dreams. Genvoya, on the other hand, is not available as a generic and is associated with fewer side effects, though it can still cause nausea and diarrhea. Both medications can worsen hepatitis B if stopped suddenly, as well as kidney problems.
